(in thousands, except useful life) 
   Useful Life
(years)
   As of
March 31,
2025
($)
   As of
March 31,
2024
($)
 
Buildings and facilities   25    2,341    2,303 
Plant and machinery   5-20    3,087    3,334 
Computer equipment’s   3    187    166 
Office equipment’s   3-5    144    140 
Furniture and fixtures   5    96    93 
Vehicles   5    58    101 
Total gross value        5,913    6,137 
Less: Accumulated depreciation        (2,693)   (2,442)
Total property, plant, and equipment, net        3,220    3,695 
Free Sentinel

Want the next IGC Pharma, Inc. pp&e disclosure the moment it drops?

Set a Sentinel and we'll alert you the moment IGC Pharma, Inc.'s next filing hits EDGAR. No credit card, your email never gets sold.

Track for free

Historical Timeline

Fiscal YearFiled
2025Jun 27, 2025Showing above
2024Jun 24, 2024
2023Jul 7, 2023
2022Jun 23, 2022
2021Jun 14, 2021
2020Jul 13, 2020
2019Jun 14, 2019
2018Jun 21, 2018
2017Jul 14, 2017
2016Jul 14, 2016

About PP&E Disclosures

The PP&E disclosure details a company's physical asset base — land, buildings, machinery, and equipment — along with the depreciation methods and useful life assumptions that determine how these costs flow through the income statement. Capitalization policy thresholds reveal management's judgment on the boundary between expense and asset, directly affecting both reported earnings and asset values.

Key signals: changes in estimated useful lives or depreciation methods can materially shift reported earnings without any operational change. Compare capital expenditures against depreciation expense — when capex consistently trails depreciation, the asset base may be aging and underinvested. Watch for large asset impairments or write-downs that signal overvalued carrying amounts. Asset retirement obligations reveal future environmental or decommissioning costs that are often underappreciated. Compare PP&E intensity (PP&E-to-revenue) against industry peers to assess capital efficiency and competitive positioning.